BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24427312)

  • 1. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
    Lee MY; Hsiao PJ; Yang YH; Lin KD; Shin SJ
    PLoS One; 2014; 9(1):e85479. PubMed ID: 24427312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone and bladder cancer: a population-based study of Taiwanese.
    Tseng CH
    Diabetes Care; 2012 Feb; 35(2):278-80. PubMed ID: 22210574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
    Korhonen P; Heintjes EM; Williams R; Hoti F; Christopher S; Majak M; Kool-Houweling L; Strongman H; Linder M; Dolin P; Bahmanyar S
    BMJ; 2016 Aug; 354():i3903. PubMed ID: 27530399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.
    Lewis JD; Ferrara A; Peng T; Hedderson M; Bilker WB; Quesenberry CP; Vaughn DJ; Nessel L; Selby J; Strom BL
    Diabetes Care; 2011 Apr; 34(4):916-22. PubMed ID: 21447663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone is not associated with an increased risk of bladder cancer.
    Tseng CH
    Cancer Epidemiol; 2013 Aug; 37(4):385-9. PubMed ID: 23619142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
    Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
    Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human insulin does not increase bladder cancer risk.
    Tseng CH
    PLoS One; 2014; 9(1):e86517. PubMed ID: 24466131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
    Hsiao FY; Hsieh PH; Huang WF; Tsai YW; Gau CS
    Drug Saf; 2013 Aug; 36(8):643-9. PubMed ID: 23797604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
    Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
    JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
    Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
    Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone use and risk of bladder cancer: population based cohort study.
    Tuccori M; Filion KB; Yin H; Yu OH; Platt RW; Azoulay L
    BMJ; 2016 Mar; 352():i1541. PubMed ID: 27029385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder cancer with pioglitazone: A case-control study.
    Malhotra B; Hiteshi P; Khalkho P; Malik R; Bhadada SK; Bhansali A; Shafiq N; Malhotra S; Kumar N; Rajput R; Rastogi A
    Diabetes Metab Syndr; 2022 Nov; 16(11):102637. PubMed ID: 36270237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
    Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
    J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
    Han E; Jang SY; Kim G; Lee YH; Choe EY; Nam CM; Kang ES
    Medicine (Baltimore); 2016 Feb; 95(6):e2786. PubMed ID: 26871835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.
    Azoulay L; Yin H; Filion KB; Assayag J; Majdan A; Pollak MN; Suissa S
    BMJ; 2012 May; 344():e3645. PubMed ID: 22653981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study.
    Jin SM; Song SO; Jung CH; Chang JS; Suh S; Kang SM; Jung I; Park CY; Kim JH; Cho JH; Lee BW
    J Korean Med Sci; 2014 Feb; 29(2):238-42. PubMed ID: 24550651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
    He S; Tang YH; Zhao G; Yang X; Wang D; Zhang Y
    Tumour Biol; 2014 Mar; 35(3):2095-102. PubMed ID: 24092576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
    Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
    Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
    Levin D; Bell S; Sund R; Hartikainen SA; Tuomilehto J; Pukkala E; Keskimäki I; Badrick E; Renehan AG; Buchan IE; Bowker SL; Minhas-Sandhu JK; Zafari Z; Marra C; Johnson JA; Stricker BH; Uitterlinden AG; Hofman A; Ruiter R; de Keyser CE; MacDonald TM; Wild SH; McKeigue PM; Colhoun HM; ;
    Diabetologia; 2015 Mar; 58(3):493-504. PubMed ID: 25481707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone use and the risk of bladder cancer.
    Kuo HW; Tiao MM; Ho SC; Yang CY
    Kaohsiung J Med Sci; 2014 Feb; 30(2):94-7. PubMed ID: 24444539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.